198 related articles for article (PubMed ID: 35734954)
21. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
[TBL] [Abstract][Full Text] [Related]
22. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice.
Cui B; Hou X; Liu M; Li Q; Yu C; Zhang S; Wang Y; Wang J; Zhuang S; Liu F
Front Pharmacol; 2022; 13():829630. PubMed ID: 36046818
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
[TBL] [Abstract][Full Text] [Related]
25. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
26. 2-Methylquinazoline derivative 23BB as a highly selective histone deacetylase 6 inhibitor alleviated cisplatin-induced acute kidney injury.
Hao Y; Guo F; Huang Z; Feng Y; Xia Z; Liu J; Li L; Huang R; Lin L; Ma L; Fu P
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894849
[TBL] [Abstract][Full Text] [Related]
27. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
28. Polycomb protein EED is required for silencing of pluripotency genes upon ESC differentiation.
Obier N; Lin Q; Cauchy P; Hornich V; Zenke M; Becker M; Müller AM
Stem Cell Rev Rep; 2015 Feb; 11(1):50-61. PubMed ID: 25134795
[TBL] [Abstract][Full Text] [Related]
29. NAM protects against cisplatin-induced acute kidney injury by suppressing the PARP1/p53 pathway.
Wu W; Fu Y; Liu Z; Shu S; Wang Y; Tang C; Cai J; Dong Z
Toxicol Appl Pharmacol; 2021 May; 418():115492. PubMed ID: 33722665
[TBL] [Abstract][Full Text] [Related]
30. Polycomb Repressive Complex 2 is essential for development and maintenance of a functional TEC compartment.
Singarapu N; Ma K; Reeh KAG; Shen J; Lancaster JN; Yi S; Xie H; Orkin SH; Manley NR; Ehrlich LIR; Jiang N; Richie ER
Sci Rep; 2018 Sep; 8(1):14335. PubMed ID: 30254371
[TBL] [Abstract][Full Text] [Related]
31. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
[TBL] [Abstract][Full Text] [Related]
32. PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation.
Healy E; Mucha M; Glancy E; Fitzpatrick DJ; Conway E; Neikes HK; Monger C; Van Mierlo G; Baltissen MP; Koseki Y; Vermeulen M; Koseki H; Bracken AP
Mol Cell; 2019 Nov; 76(3):437-452.e6. PubMed ID: 31521505
[TBL] [Abstract][Full Text] [Related]
33. Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2.
Justin N; Zhang Y; Tarricone C; Martin SR; Chen S; Underwood E; De Marco V; Haire LF; Walker PA; Reinberg D; Wilson JR; Gamblin SJ
Nat Commun; 2016 Apr; 7():11316. PubMed ID: 27121947
[TBL] [Abstract][Full Text] [Related]
34. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
35. First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Moody JD; Levy S; Mathieu J; Xing Y; Kim W; Dong C; Tempel W; Robitaille AM; Dang LT; Ferreccio A; Detraux D; Sidhu S; Zhu L; Carter L; Xu C; Valensisi C; Wang Y; Hawkins RD; Min J; Moon RT; Orkin SH; Baker D; Ruohola-Baker H
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10125-10130. PubMed ID: 28864533
[TBL] [Abstract][Full Text] [Related]
36. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
[TBL] [Abstract][Full Text] [Related]
37. Two Functional Axes of Feedback-Enforced PRC2 Recruitment in Mouse Embryonic Stem Cells.
Perino M; van Mierlo G; Loh C; Wardle SMT; Zijlmans DW; Marks H; Veenstra GJC
Stem Cell Reports; 2020 Dec; 15(6):1287-1300. PubMed ID: 32763159
[TBL] [Abstract][Full Text] [Related]
38. The central role of EED in the orchestration of polycomb group complexes.
Cao Q; Wang X; Zhao M; Yang R; Malik R; Qiao Y; Poliakov A; Yocum AK; Li Y; Chen W; Cao X; Jiang X; Dahiya A; Harris C; Feng FY; Kalantry S; Qin ZS; Dhanasekaran SM; Chinnaiyan AM
Nat Commun; 2014; 5():3127. PubMed ID: 24457600
[TBL] [Abstract][Full Text] [Related]
39. Mutations in genes encoding polycomb repressive complex 2 subunits cause Weaver syndrome.
Imagawa E; Higashimoto K; Sakai Y; Numakura C; Okamoto N; Matsunaga S; Ryo A; Sato Y; Sanefuji M; Ihara K; Takada Y; Nishimura G; Saitsu H; Mizuguchi T; Miyatake S; Nakashima M; Miyake N; Soejima H; Matsumoto N
Hum Mutat; 2017 Jun; 38(6):637-648. PubMed ID: 28229514
[TBL] [Abstract][Full Text] [Related]
40. EZH2 has a non-catalytic and PRC2-independent role in stabilizing DDB2 to promote nucleotide excision repair.
Koyen AE; Madden MZ; Park D; Minten EV; Kapoor-Vazirani P; Werner E; Pfister NT; Haji-Seyed-Javadi R; Zhang H; Xu J; Deng N; Duong DM; Pecen TJ; Frazier Z; Nagel ZD; Lazaro JB; Mouw KW; Seyfried NT; Moreno CS; Owonikoko TK; Deng X; Yu DS
Oncogene; 2020 Jun; 39(25):4798-4813. PubMed ID: 32457468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
